{
    "organizations": [],
    "uuid": "4ee65d6a0b29c8bd26e0c7de1261f38b6416853e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-gsk-to-review-of-horlicks-consumer/brief-gsk-to-review-of-horlicks-consumer-nutrition-products-to-fund-novartis-deal-idUSFWN1R814E",
    "ord_in_thread": 0,
    "title": "BRIEF-GSK To Review Of Horlicks, Consumer Nutrition Products To Fund Novartis Deal",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27, 2018 / 5:17 AM / Updated 24 minutes ago BRIEF-GSK To Review Of Horlicks, Consumer Nutrition Products To Fund Novartis Deal Reuters Staff 2 Min Read March 27 (Reuters) - Glaxosmithkline Plc: * GLAXOSMITHKLINE - TRANSACTION WITH NOVARTIS EXPECTED TO BE ACCRETIVE TO ADJUSTED EARNINGS IN 2018 AND THEREAFTER, AND TO STRENGTHEN CASH FLOW GENERATION * GSK ALSO TO INITIATE STRATEGIC REVIEW OF HORLICKS AND OTHER CONSUMER NUTRITION PRODUCTS TO SUPPORT TRANSACTION FUNDING. * ‍REVIEW WILL INCLUDE AN ASSESSMENT OF GROUP’S SHAREHOLDING IN INDIAN SUBSIDIARY, GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD​ * STRATEGIC REVIEW WILL INCLUDE AN ASSESSMENT OF GSK’S 72.5% SHAREHOLDING IN COMPANY * ‍EXPECTS OUTCOME OF STRATEGIC REVIEW TO BE CONCLUDED AROUND END OF 2018​ * GLAXOSMITHKLINE - CONSUMER HEALTHCARE BUSINESS TO CONTINUE TO INVEST IN GROWTH OPPORTUNITIES FOR OTC, ORAL HEALTH BRANDS, SUCH AS SENSODYNE AND ENO * GLAXOSMITHKLINE - ACTIVELY INVESTING IN PHARMACEUTICAL, VACCINES BUSINESSES, INCLUDING BUILDING NEW MANUFACTURING CAPACITY IN VEMGAL, KARNATAKA, NASHIK * GLAXOSMITHKLINE - BUYOUT TO BE STRUCTURED AS CANCELLATION OF NOVARTIS’ SHARES IN JV IN CONSIDERATION OF JOINT VENTURE PAYING BUYOUT PRICE TO NOVARTIS * GSK HAS ENTERED INTO A COMMITTED FACILITIES AGREEMENT TO SUPPORT FUNDING OF BUYOUT * AGREED TO PAY BREAK FEE OF $200 MILLION IN NOVARTIS DEAL * JOINT VENTURE WILL CONTINUE TO PAY DIVIDENDS TO GSK AND NOVARTIS IN ACCORDANCE WITH ITS ESTABLISHED PRACTICE UNTIL COMPLETION Further company coverage:",
    "published": "2018-03-27T08:17:00.000+03:00",
    "crawled": "2018-03-27T08:49:03.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "review",
        "horlicks",
        "consumer",
        "nutrition",
        "product",
        "fund",
        "novartis",
        "deal",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "glaxosmithkline",
        "plc",
        "glaxosmithkline",
        "transaction",
        "novartis",
        "expected",
        "accretive",
        "adjusted",
        "earnings",
        "thereafter",
        "strengthen",
        "cash",
        "flow",
        "generation",
        "gsk",
        "also",
        "initiate",
        "strategic",
        "review",
        "horlicks",
        "consumer",
        "nutrition",
        "product",
        "support",
        "transaction",
        "funding",
        "include",
        "assessment",
        "group",
        "shareholding",
        "indian",
        "subsidiary",
        "glaxosmithkline",
        "consumer",
        "healthcare",
        "strategic",
        "review",
        "include",
        "assessment",
        "gsk",
        "shareholding",
        "company",
        "outcome",
        "strategic",
        "review",
        "concluded",
        "around",
        "end",
        "glaxosmithkline",
        "consumer",
        "healthcare",
        "business",
        "continue",
        "invest",
        "growth",
        "opportunity",
        "otc",
        "oral",
        "health",
        "brand",
        "sensodyne",
        "eno",
        "glaxosmithkline",
        "actively",
        "investing",
        "pharmaceutical",
        "vaccine",
        "business",
        "including",
        "building",
        "new",
        "manufacturing",
        "capacity",
        "vemgal",
        "karnataka",
        "nashik",
        "glaxosmithkline",
        "buyout",
        "structured",
        "cancellation",
        "novartis",
        "share",
        "jv",
        "consideration",
        "joint",
        "venture",
        "paying",
        "buyout",
        "price",
        "novartis",
        "gsk",
        "entered",
        "committed",
        "facility",
        "agreement",
        "support",
        "funding",
        "buyout",
        "agreed",
        "pay",
        "break",
        "fee",
        "million",
        "novartis",
        "deal",
        "joint",
        "venture",
        "continue",
        "pay",
        "dividend",
        "gsk",
        "novartis",
        "accordance",
        "established",
        "practice",
        "completion",
        "company",
        "coverage"
    ]
}